The Company is in search of buyer that will fully commercialize its unique and patented biofeedback device for the treatment of dysphagia. Dysphagia is a common and costly problem. Effective solutions include intensive swallowing exercises, but solutions include intensive swallowing exercises, but these are rarely completed by patients with the intensity and frequency prescribed. Untreated or under-treated dysphagia results in poor health outcomes for patients such as dehydration, malnutrition, placement of feeding tubes, aspiration pneumonia, depression and death. These outcomes translate into increased healthcare costs such as repeated hospital admissions, longer stays and more frequent medical follow up.

The Company's device has received FDA 510K Class II clearance and has both US and Canadian patents. The Company currently has 77 institutions using the device and there are an additional 14 companies in the pipeline. It is the only FDA cleared device capable of Real Time Monitoring used for dysphagia.

NDA is required to secure comprehensive Executive Summary crafted by ProNova Partners.

Detailed Information

Facilities: Portable worldwide.

Competition: In CIM / NDA required.

Growth & Expansion: Primed for growth with the Buyer.

Financing: TBD if structure and terms are acceptable.

Support & Training: As needed � specific terms for transition support can be negotiated. The Seller wishes to facilitate a successful and smooth transfer of the Business.

Reason for Selling: Other business interests.